Unregulated Peptides Pose Health Risks Due to Lack of Purity Testing, Warns UVA Health Director
Catherine Varney, DO, obesity medicine director at UVA Health, is warning about the significant health risks associated with unregulated 'gray market' peptides. These products, often promoted aggressively on social media as alternatives to FDA-approved therapies, frequently contain far less active ingredient than advertised and can be contaminated with toxic impurities, such as arsenic, at levels up to 10 times acceptable limits. Varney notes that the market for unapproved peptides has surged since FDA-approved versions like liraglutide, semaglutide, and tirzepatide became widely used around 2021. Patients who cannot afford approved medications are turning to these unregulated sellers, a market projected to reach $50 billion to $75 billion by 2028. Unlike FDA-approved peptides, which undergo rigorous preclinical, animal, and human studies, gray market products lack established safety and efficacy data in humans, with evidence largely resting on animal studies.
